Economic incentives and patent protections drive development of innovative medications. Drug prices are determined by consumer demand, not production costs. Therefore, governmental regulation risks future investment in research and development.
M. Christopher Roebuck, PhD
Advertisement
Articles by M. Christopher Roebuck, PhD
Curative direct-acting antivirals for chronic hepatitis C provide a net economic benefit to Medicaid in less than 1 year. Cumulative savings to date have exceeded $15 billion.
Advertisement
Latest Updated Articles
The Price of Progress: Understanding Innovation and Affordability of Prescription DrugsPublished: October 7th 2024 | Updated:
- Impact of Direct-Acting Antiviral Use for Chronic Hepatitis C on Health Care Costs in Medicaid: Economic Model Update
Published: December 12th 2022 | Updated:
- Assessing the Burden of Illness of Chronic Hepatitis C and the Impact of Direct-Acting Antiviral Use on Healthcare Costs in Medicaid
Published: June 18th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
Near Low–Income Medicare Beneficiaries Face More Affordability Problems Than Other Income Groups
3
Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting
4
Childhood Insurance Dynamics Predict Medicaid Cuts Will Widen Gaps
5
